Überprüfung…
Automatisch übersetzt. Dosierung und Warnhinweise: bitte im englischen Original prüfen. Auf Englisch lesen
Homepage / Arzneimittel A–Z / Satralizumab

Satralizumab

ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patien.

Checked against the official label · Updated

Prescription medicine Subcutaneous

Satralizumab: quick answers

Used for
ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in.
Children
Prescription
Prescription medicine in the United States; rules differ by country.

From the official label (Oct 2026). Your prescription and pharmacist come first.

How to use Satralizumab

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients. ( 1.2 ) 1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. 1.2 Thyroid Eye Disease (TED) ENSPRYNG is indicated for the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients.

How to take it and how often
  • Hepatitis B virus, tuberculosis, and liver transaminase screening is required before the first dose
  • Prior to every use, determine if there is an active infection
  • The recommended loading dosage of ENSPRYNG is: NMOSD: for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks
  • TED: for body weight 40-100kg; for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks
  • For body weight >100 kg: for the first three administrations is 180 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 180 mg every 4 weeks See Full Prescribing Information for important preparation and administration instructions
  • Assessments Prior to the First Dose of ENSPRYNG Hepatitis B Virus Screening Prior to initiating ENSPRYNG, perform Hepatitis B virus (HBV) screening
  • ENSPRYNG is contraindicated in patients with active HBV confirmed by positive results for surface antigen [HBsAg] and anti-HBV tests
  • For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment with ENSPRYNG [see Contraindications and Warnings and Precautions ]
  • Tuberculosis Screening Prior to initiating ENSPRYNG, evaluate for active tuberculosis and test for latent infection. …
Strengths it comes in

ENSPRYNG is a clear, and colorless to slightly yellow solution available as: Injection: 120 mg/mL in single-dose prefilled syringe. Injection: 120 mg/mL in single-dose autoinjector. Injection: 180 mg/1.5 mL in single-dose autoinjector Injection: 120 mg/mL in a single-dose prefilled syringe ( 3 ) Injection: 120 mg/mL in a single-dose prefilled autoinjector ( 3 ) Injection: 180 mg/1.5 mL in a single …

Children
  • Safety and effectiveness
  • In pediatric patients have not been established
Older adults

Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. However, population pharmacokinetic analyses in patients with NMOSD and TED did not show that age affected the pharmacokinetics of satralizumab-mwge [see Clinical Pharmacology (12.3) ] . …

While you are taking it
  • Advise the patients to read the FDA-approved patient labeling ( Medication Guide and Instructions for Use )
  • Infections Inform patients that an increased risk of infections, including serious and potentially fatal infections, has been observed in patients treated with IL-6 receptor antagonists, including ENSPRYNG
  • Instruct patients to contact their healthcare provider immediately when symptoms suggesting infection (e.g., fever, chills, constant cough, or sore throat) appear during treatment [see Warning and Precautions ] . …
Talk to a doctor first if

ENSPRYNG is contraindicated in patients with: A known hypersensitivity to satralizumab or any of the inactive ingredients [see Warnings and Precautions (5.4) ] Active Hepatitis B infection [see Warnings and Precautions (5.1) ] Active or untreated latent tuberculosis [see Warnings and Precautions (5.1) ] Known hypersensitivity to satralizumab or any of the inactive ingredients ( 4 ) Active Hepatitis B infection ( 4 ) Active or untreated latent tuberculosis ( 4 )

Warnings

Infections: Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live-attenuated vaccines is not recommended during treatment. ( 5.1 ) Elevated Liver Enzymes: Monitor ALT and AST levels during treatment; interruption of ENSPRYNG may be required. ( 5.2 ) Decreased Neutrophil Counts: Monitor neutrophils during treatment. ( 5.3 ) 5.1 Infections An increased risk of infections, including serious and potentially fatal infections, has been observed in patients treated with IL-6 receptor antagonists, including ENSPRYNG. …

Possible side effects

The following clinically significant adverse reactions are described elsewhere in the labeling: Infections [see Warnings and Precautions (5.1) ] Elevated Liver Enzymes [see Warnings and Precautions (5.2) ] Decreased Neutrophil Counts [see Warnings and Precautions (5.3) ] Hypersensitivity Reactions [see Warnings and Precautions (5.4) ] The most common adverse reactions in patients with NMOSD (incidence at least 15%) are nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea. …

Pregnancy and breastfeeding

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women with NMOSD exposed to ENSPRYNG during pregnancy. Healthcare providers are encouraged to register NMOSD patients and pregnant women with NMOSD are encouraged to register themselves by calling 1-833-277-9338. …

How to store it

Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake. ENSPRYNG can be stored out of refrigeration for a maximum of 8 days at a temperature that does not exceed 30°C (86°F). …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-10-23.

How much Satralizumab costs

In other countries

Prices in other countries are not what you will pay where you live; they show how prices compare.

Brands around the world

Products with Satralizumab as the active ingredient. Names differ between countries.

Registered products

United States (FDA)

SatralizumabSATRALIZUMAB 120 mg/mL · Injection, Solution · Chugai Pharmaceutical Co., Ltd.
NDC 60422-367Label
SatralizumabSATRALIZUMAB 120 mg/mL · Injection, Solution · Chugai Pharmaceutical Co., Ltd.
NDC 60422-370Label
SatralizumabSATRALIZUMAB 120 mg/mL · Injection, Solution · Chugai Pharmaceutical Co., Ltd.
NDC 60422-380Label
EnspryngSATRALIZUMAB 180 mg/1.5mL · Injection, Solution · Genentech, Inc.
NDC 50242-005Label
EnspryngSATRALIZUMAB 120 mg/mL · Injection, Solution · Genentech, Inc.
NDC 50242-007Label

Nigeria (NAFDAC)

NAFDACEnspryng Solution for Injection A6-100128

Other countries: check your pack's registration number and we point you to your regulator.

Check your pack of Satralizumab

Type the registration number on the pack, or scan it with your camera.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

Questions about Satralizumab

What is Satralizumab used for?

ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients. ( 1.2 ) 1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) ENSPRYNG is indicated for the treatment of neuro (From the official U.S. FDA label.)

How do I take Satralizumab?

Follow your prescription or the leaflet in your pack. The official label says: Hepatitis B virus, tuberculosis, and liver transaminase screening is required before the first dose. ( 2.1 ) Prior to every use, determine if there is an active infection. ( 2.2 ) The recommended loading dosage of ENSPRYNG is: NMOSD: for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 w…

Do I need a prescription for Satralizumab?

Usually yes. Satralizumab is a prescription medicine in most countries. Rules differ by country.

What brands contain Satralizumab?

Satralizumab is sold under names such as Enspryng. Brand names differ between countries.

What are the side effects of Satralizumab?

The official label lists: The following clinically significant adverse reactions are described elsewhere in the labeling: Infections [see Warnings and Precautions (5.1) ] Elevated Liver Enzymes [see Warnings and Precautions (5.2) ] Decreased Neutrophil Counts [see Warnings and Precautions (5.3) ] Hypersensitivity Reactions [see Warnings and Precautions (5.4) ] The most common adverse reactions in patien… Tell your doctor about any side effect that bothers you or does not go away.

Can children take Satralizumab?

Safety and effectiveness in pediatric patients have not been established. Always use the dose for the child's age or weight on the pack or prescription.

Can I take Satralizumab when pregnant or breastfeeding?

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women with NMOSD exposed to ENSPRYNG during pregnancy. Healthcare providers are encouraged to register NMOSD patients and pregnant women with NMOSD are encouraged to register themselves by calling 1-833-277-9338. … Ask your doctor or midwife first.

How should I store Satralizumab?

Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake. ENSPRYNG can be stored out of refrigeration for a maximum of 8 days at a temperature that does not exceed 30°C (86°F). …

How can I check that my Satralizumab is genuine?

Scan the registration number on your pack with PillVera (NAFDAC number in Nigeria, NDC in the United States, DIN in Canada), check the expiry date and buy only from licensed pharmacies.

Sources

This page shows what official sources say, in plain words. It is not medical advice: your prescription and your doctor or pharmacist come first. Brand names, strengths and rules differ between countries.